TickerTalks
Browse all tickers →
TickerTalks›$HCAT
HCHCAT

Health Catalyst, Inc.

$HCAT·$128M·Medical - Healthcare Information Services·Healthcare
$1.71+1.2%YTD-13.0%1Y-50.3%
Mentions · last 7 days
2026-08-27: 0 posts2026-08-28: 0 posts2026-08-29: 0 posts2026-08-30: 1 posts2026-08-31: 1 posts2026-09-01: 1 posts2026-09-02: 2 posts5
Price updated 2m ago·X counts updated 1d ago
HCHCAT
$HCATHealth Catalyst, Inc.
$1.71+1.18%5 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $HCAT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-08-21

Falling on heavy selling — points lower unless it turns around.

Healthcare-data-analytics vendor shrinking again — the SaaS growth story cracked and the tape is confirming.

Health Catalyst sells a data-and-analytics platform to US healthcare systems — the intended job is helping providers analyze clinical, operational, and financial data to improve outcomes and reduce cost. It's been a slow-growth SaaS story that has now slid into contraction.

  • Q1 revenue was down 11% year-on-year to $70.8M — the fifth straight quarter of negative revenue growth, so the SaaS-scale narrative is broken, not paused.
  • Trades at ~0.47x sales — a genuinely cheap multiple, but at this growth trajectory it is 'cheap on the way down' rather than a coiled value case; every quarter of continued decline resets 'fair' lower.
  • Q2 EPS came in at $0.04 vs $0.03 consensus — technically a beat, but on tiny denominators; the operating loss for the trailing period is what matters more than the ex-item EPS.
  • Sits at the 24th percentile of its 52-week range, is 15% below the 200-day trend, and -44% over 12 months — the tape has been in distribution for a year, and the fundamentals have followed rather than resisted.

What restarts the move is Nov 9 Q3 landing revenue year-on-year less-negative alongside a specific bookings pipeline number that separates 'declining base plus real new business' from 'declining base plus nothing.' What confirms the breakdown is a sixth straight negative quarter or a fresh customer-departure headline; at a $128M market cap, this equity is one large customer loss away from a whole new fair-value zone.

What to watch: Nov 9 Q3 earnings — revenue growth trajectory is the number. Watch for bookings/backlog disclosure and any commentary on large-customer renewals.

On the calendar: 2026-11-09 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-08-30

Chatter is exclusively about the Lo0p HyperEVM cat memecoin, not Health Catalyst. Boosters cheer $HCAT running from a $50K share to $100K market cap, $20M in supply already burned through fees, $250K of platform volume processed and a locked-forever HyperSwap pool against HYPE. Posters call it 'the only thing worth buying in the hype trenches' and frame it as the first-mover cat token on the launchpad. Uniformly promotional.

Read the AI verdict + X sentiment for $HCAT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Data and analytics platform for healthcare systems, integrating clinical and operational data for performance improvement.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $HCAT.

Medical - Healthcare Information Services · Healthcare

Healthcare IT adoption — EHR optimization, AI-assisted coding, and clinical decision support — is the structural demand driver. CMS reimbursement model shifts toward value-based care accelerate analytics and connectivity investment.

What this means for $HCAT

Direct beneficiary — AI-native product or platform captures spend from the same capex cycle driving the industry; Data and analytics platform for healthcare systems, integrating clinical and operational data for performance improvemen.

Industry benchmark

10-name peer basket
+34.3%YTD
+38.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-18.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-19.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-99.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
46.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$0.04$0.03+33.9%
Q1 2026May 11, 2026$0.02$0.01+100.0%
Q4 2025Mar 12, 2026$0.08$0.09-11.1%
Q3 2025Nov 10, 2025$0.06$0.05+20.0%
Next earningsMon, Nov 9·consensus EPS $-0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$70.8M-10.9%33.4%-9.5%$-1.53$13.6M
Q4 FY25$74.7M-6.2%52.7%4.4%$-1.28$9.6M
Q3 FY25$76.3M-0.0%49.5%-22.9%$-0.32$-5.3M
Q2 FY25$80.7M+6.3%47.4%-46.0%$-0.59$-8.8M

Forward consensus

3-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$263.3M$261.6M – $264.2M$0.04-$0.21 – $0.255
FY27$247.1M$233.3M – $272.3M$0.09-$0.32 – $0.515
FY28$247.1M$240.1M – $254.0M$0.03$0.02 – $0.032

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.28%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-14.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-9.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 61.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.565-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 14 other (7 awards · 7 inkinds) in window

See when $HCAT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAcquisition completedAug 68-K — Item 1.02: Agreement terminated · Item 2.01: Acquisition completed · Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

HEALTH CATALYST, INC. (HCAT) reported Q2 2026 financial results on 2026-08-06, reporting financial results details in attached press release. The press release notes: below) together with cash on hand, voluntarily repaid in ful. Additional items: Item 1.02, Item 2.01, Item 7.01. Quarterly earnings are a material disclosure; investors should review the full press release for segment details and management commentary.

8-KShareholder voteJul 208-K — Item 5.07: Shareholder vote
AI summary

Health Catalyst, Inc. (HCAT) held its 2026 Annual Meeting on July 16, 2026, with 54.4M of 73.9M eligible shares represented. Stockholders elected two Class I directors — Justin Spencer (41.2M for, 0.9M withheld) and Mathew Arens (40.6M for, 1.5M withheld) — each to three-year terms expiring in 2029, and ratified Ernst & Young LLP as independent auditor for FY2026. No contested votes or notable withhold campaigns. Standard annual meeting housekeeping with no material market impact.

SC 13DActivist position (5%+)Jun 22SC 13D
AI summary

Schedule 13D filed by Palogic Value Management, LP reporting beneficial ownership of SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Health Catalyst, Inc. representing a 7% stake (4 shares), with investment intent. This SC 13D filing dated 2026-06-22 updates the holder's position and disclosed intentions.

SC 13D/AActivist amendmentJun 8SC 13D/A
AI summary

With filed Amendment No. 2 to Schedule 13D disclosing updated beneficial ownership in HCAT (HCAT). The filing covers approximately 3,285,690 shares of HCAT. The position is held for potential M&A activity. Schedule 13D amendments are required when a 5%-or-greater holder's ownership, intent, or plans change materially, providing transparency into concentrated positions that could influence corporate governance or trigger M&A activity.

8-KMaterial agreementJun 48-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

HCAT (HCAT) disclosed a material definitive agreement under Item 1.01, reporting a merger or acquisition transaction involving growth company as defined in Rule. The deal is valued at approximately $0. Details of the transaction terms, consideration structure, and closing conditions are set forth in the full 8-K filing. Definitive merger agreements are among the most material events a public company can disclose, triggering regulatory review and shareholder vote requirements.

3New insider — initial holdingsMay 43
AI summary

A new insider filed a Form 3 with the SEC, disclosing initial beneficial ownership of HCAT securities. This filing is required under Section 16(a) of the Securities Exchange Act within 10 days of becoming a reporting person (officer, director, or 10%+ holder). The filing reports 4 shares of common stock. Form 3 filings establish a baseline ownership record for subsequent Form 4 (changes) and Form 5 (annual) filings, providing transparency into insider positions at HCAT.

8-KOfficer or director changeApr 308-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

HCAT (HCAT) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in President. Individuals named in the filing include Employer Identification, South River. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KOfficer or director changeApr 278-K — Item 5.02: Officer or director change · Item 8.01: Other event
AI summary

HCAT (HCAT) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in CTO. Individuals named in the filing include Employer Identification, South River. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

+ 17 other (5 13Gs · 2 10-Qs · 2 proxys · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Hsbc Holdings PLC Invests $809,000 in Health Catalyst, Inc. $HCATdefenseworld.net·2d agoHealth Catalyst to Participate in Upcoming Investor Conferenceglobenewswire.com·3d agoCritical Survey: Aclarion (NASDAQ:ACONW) and Health Catalyst (NASDAQ:HCAT)defenseworld.net·11d agoHealth Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of “Hold” from Analystsdefenseworld.net·23d agoHealth Catalyst (NASDAQ:HCAT) and Lynx Global Digital Finance (OTCMKTS:CNONF) Head-To-Head Reviewdefenseworld.net·23d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$HTFL$HNGE$SY$DOCS$TXG$WGS$TDOC
Voices on X · last 7 days

No standout posts about $HCAT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport